The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, Larry Ereshefsky et al.|Science Translational Medicine|2016Cited by 416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew Fell, John A. Morrow, Boonlert Cheewatrakoolpong et al.|Journal of Pharmacology and Experimental Therapeutics|2015Cited by 336
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s DiseaseJack D. Scott, Andrew W. Stamford, Mark S. Forman et al.|Journal of Medicinal Chemistry|2016Cited by 165
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D. Scott, Michael W. Miller, John A. McCauley et al.|Journal of Medicinal Chemistry|2017Cited by 147
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ ReductionAndrew W. Stamford, William J. Greenlee, Peter Orth et al.|ACS Medicinal Chemistry Letters|2012Cited by 99